FDA
-
-
-
-
-
-
-
FDA panel set to review GRAIL's multi-cancer blood test application
-
-
-
-
-
-
-
Goldman Sachs Starts GRAIL, Inc. (GRAL) at Neutral
-
-
-
-
-
-
-
Mizuho Starts GRAIL, Inc. (GRAL) at Neutral
-
-
-
-
-
-
-
TD Cowen Upgrades GRAIL, Inc. (GRAL) to Buy
-
-
-
-
-
-
-
Baird Starts GRAIL, Inc. (GRAL) at Outperform
-
-
-
-
-
-
-
GRAIL study shows cancer test positive predictive value rises to 84.2%
-
-
-
-
-
-
-
GRAIL to Present New GalleriĀ® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC
-
332,175 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

